Literature DB >> 31813850

The global burden of neurological disorders: translating evidence into policy.

Valery L Feigin1, Theo Vos2, Emma Nichols2, Mayowa O Owolabi3, William M Carroll4, Martin Dichgans5, Günther Deuschl6, Priya Parmar7, Michael Brainin8, Christopher Murray2.   

Abstract

Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. In the past 30 years, the absolute numbers of deaths and people with disabilities owing to neurological diseases have risen substantially, particularly in low-income and middle-income countries, and further increases are expected globally as a result of population growth and ageing. This rise in absolute numbers of people affected suggests that advances in prevention and management of major neurological disorders are not sufficiently effective to counter global demographic changes. Urgent measures to reduce this burden are therefore needed. Because resources for health care and research are already overstretched, priorities need to be set to guide policy makers, governments, and funding organisations to develop and implement action plans for prevention, health care, and research to tackle the growing challenge of neurological disorders.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31813850     DOI: 10.1016/S1474-4422(19)30411-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  54 in total

Review 1.  CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders.

Authors:  Lihong Guan; Yawei Han; Ciqing Yang; Suxiang Lu; Jiang Du; Han Li; Juntang Lin
Journal:  Mol Neurobiol       Date:  2021-11-23       Impact factor: 5.590

2.  Development and internal validation of a prognostic model for 15-year risk of Alzheimer dementia in primary care patients.

Authors:  Giulia Grande; Davide L Vetrano; Ettore Marconi; Elisa Bianchini; Iacopo Cricelli; Valeria Lovato; Luisa Guglielmini; Daiana Taddeo; Stefano F Cappa; Claudio Cricelli; Francesco Lapi
Journal:  Neurol Sci       Date:  2022-07-18       Impact factor: 3.830

3.  Meaning in life and risk of cognitive impairment: A 9-Year prospective study in 14 countries.

Authors:  Angelina R Sutin; Martina Luchetti; Yannick Stephan; Antonio Terracciano
Journal:  Arch Gerontol Geriatr       Date:  2020-03-05       Impact factor: 3.250

Review 4.  Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside.

Authors:  Awanish Mishra; Ritam Bandopadhyay; Prabhakar Kumar Singh; Pragya Shakti Mishra; Neha Sharma; Navneet Khurana
Journal:  Metab Brain Dis       Date:  2021-08-13       Impact factor: 3.584

5.  Is There Any Association Between Neurodegenerative Diseases and Periodontitis? A Systematic Review.

Authors:  María Olimpia Paz Alvarenga; Deborah Ribeiro Frazão; Isabella Gomes de Matos; Leonardo Oliveira Bittencourt; Nathália Carolina Fernandes Fagundes; Cassiano Kuchenbecker Rösing; Lucianne Cople Maia; Rafael Rodrigues Lima
Journal:  Front Aging Neurosci       Date:  2021-05-24       Impact factor: 5.750

6.  Global survey on disruption and mitigation of neurological services during COVID-19: the perspective of global international neurological patients and scientific associations.

Authors:  Chahnez Charfi Triki; Matilde Leonardi; Salma Zouari Mallouli; Martina Cacciatore; Kimberly Coard Karlshoej; Francesca Giulia Magnani; Charles R Newton; Andrea Pilotto; Deanna Saylor; Erica Westenberg; Donna Walsh; Andrea Sylvia Winkler; Kiran T Thakur; Njideka U Okubadejo; David Garcia-Azorin
Journal:  J Neurol       Date:  2021-06-11       Impact factor: 4.849

7.  Crocetin as New Cross-Linker for Bioactive Sericin Nanoparticles.

Authors:  Sara Perteghella; Giovanna Rassu; Elisabetta Gavini; Antonella Obinu; Elia Bari; Delia Mandracchia; Maria Cristina Bonferoni; Paolo Giunchedi; Maria Luisa Torre
Journal:  Pharmaceutics       Date:  2021-05-09       Impact factor: 6.321

8.  Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.

Authors:  Messoud Ashina; Joshua M Cohen; Maja Galic; Verena Ramirez Campos; Steve Barash; Xiaoping Ning; Yoel Kessler; Lindsay Janka; Hans-Christoph Diener
Journal:  J Headache Pain       Date:  2021-07-10       Impact factor: 7.277

9.  Lay Public View of Neuroscience and Science-Based Brain Health Recommendations in Slovenia.

Authors:  Nastja Tomat; Matej Perovnik; Gaj Vidmar; Vesna van Midden; Sara Fabjan; Hana Hawlina; Dolores Trol; Alina Holnthaner; Sebastijan Krajnc; Maruša Grešak; Liza Žerdin; Judita Vidmar; Mara Bresjanac
Journal:  Front Public Health       Date:  2021-07-01

10.  Neuroscience education and research in Cameroon: Current status and future direction.

Authors:  Ngala Elvis Mbiydzenyuy; Constant Anatole Pieme; Richard E Brown; Carine Nguemeni
Journal:  IBRO Neurosci Rep       Date:  2021-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.